Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

HomeCirculationVol. 113, No. 13Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBArrhythmogenic Right Ventricular Cardiomyopathy/DysplasiaClinical Impact of Molecular Genetic Studies Domenico Corrado, MD, PhD and Gaetano Thiene, MD Domenico CorradoDomenico Corrado From the Department of Cardiac, Thoracic, and Vascular Sciences (D.C.) and Institute of Pathological Anatomy (G.T.), University of Padua Medical School, Padua, Italy. and Gaetano ThieneGaetano Thiene From the Department of Cardiac, Thoracic, and Vascular Sciences (D.C.) and Institute of Pathological Anatomy (G.T.), University of Padua Medical School, Padua, Italy. Originally published4 Apr 2006https://doi.org/10.1161/CIRCULATIONAHA.105.616490Circulation. 2006;113:1634–1637Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inherited heart muscle disease that predominantly affects the right ventricle (RV). It is characterized pathologically by RV myocardial atrophy with fibrofatty replacement and clinically by ventricular electric instability with ventricular tachycardia or ventricular fibrillation that may lead to sudden death, primarily in young people and athletes.1 Later in the disease evolution, progression of RV muscle disease and left ventricular involvement may result in heart failure.2 The condition was initially believed to be a developmental defect of the RV myocardium, leading to the original designation of "dysplasia." This concept has evolved over the last 25 years into the current perspective of a genetically determined "cardiomyopathy."3 Clinical diagnosis of ARVC/D is often difficult because of the nonspecific nature of disease features and the broad spectrum of phenotypic manifestations. The advent of the molecular genetic era has provided new insights in understanding the pathophysiology of ARVC/D, showing that it is a desmosomal disease resulting from defective cell adhesion proteins such as plakoglobin, desmoplakin, plakophilin-2, and desmoglein-2.4–7 The availability of molecular testing for mutation screening of disease genes offers the possibility to identify genetically affected individuals. Potential clinical impact of genotype determination includes diagnosis (family screening and preclinical diagnosis); prediction of clinical phenotype (penetrance, gene-specific clinical manifestations); risk stratification (assessment of malignant versus benign mutations); clinical and genetic counseling (restriction of physical activity, family planning); and therapy (prevention of sudden death by implantable cardioverter/defibrillator [ICD]).Articles p 1641 and p 1650In this issue of Circulation, studies by Dalal et al8 in the United States and van Tintelen et al9 in the Netherlands address the prevalence and clinical expression of mutations in the plakophilin-2 gene (PKP2) in ARVC/D patient populations of comparable size and fulfilling the task force diagnostic criteria.10 On both sides of the ocean, a defective PKP2 gene appears to be a major cause of ARVC/D with a prevalence of mutations among unrelated index cases as high as 43% (a figure curiously identical in both studies). In the Dutch study, PKP2 mutations were distinctively identified in ARVC/D probands with familial disease (16 of 23; 70%); no PKP2 mutations were found in patients with an apparently "sporadic" phenotype (0 of 16; P<0.001). In both studies there were no significant differences with regard to clinical characteristics and events during follow-up between PKP2 mutation–positive probands and those in whom no mutation was identified. These findings deserve careful consideration because they may remarkably affect our diagnostic approach to ARVC/D, given the concrete possibility of preclinical identification of genetically affected individuals. On the other hand, they point out the limited value of molecular genetic analysis for predicting clinical phenotype and risk of sudden death.Genetics and PathophysiologyThe estimated prevalence of ARVC/D in the general population ranges from 1 in 2000 to 1 in 5000. The disease affects men more frequently than women, with an approximate ratio of 3:1. A familial background has been demonstrated in >50% of ARVC/D cases. The disease is usually inherited as an autosomal dominant trait with incomplete penetrance and variable expression. The first chromosomal locus (14q23-q24) was published in 1994 after clinical evaluation of a large Italian family.11 Subsequently, linkage analysis provided evidence for genetic heterogeneity with sequential discovery of several ARVC/D loci on chromosomes 1, 2, 3, 6, 10, 12, and 14. An autosomal recessive variant of ARVC/D (so-called Naxos disease) in which there is a cosegregation of cardiac (ARVC/D), skin (palmoplantar keratosis), and hair (woolly hair) abnormalities has been mapped on chromosome 17 (locus 17q21). The first disease-causing gene, the JUP gene, was identified by McKoy and colleagues4 in patients with Naxos disease. The gene encodes the desmosomal protein plakoglobin, a major constituent of cell adhesion junction. Its discovery suggested that ARVC/D is a cell-to-cell junction disease and stimulated the research in other related genes. Desmoplakin gene (DSP) was the first desmosomal protein gene to be associated with the more common autosomal dominant form of ARVC/D by Rampazzo et al.5 Gerull et al6 identified 25 different mutations in the gene encoding plakophilin-2 (PKP2). Most recently, desmoglein-2 gene (DSG-2) mutations have been found in 10% of ARVC/D unrelated probands.7 This consistent type of protein alteration supports the concept of "final common pathway" of genetically determined cardiomyopathies, ARVC/D being deemed a desmosomal disease, hypertrophic cardiomyopathy a sarcomeric disease, and dilated cardiomyopathy a cytoskeletal disease,12 with some exceptions.Autosomal dominant ARVC/D has been linked to other genes unrelated to cell adhesion complex, such as the gene encoding for cardiac ryanodine receptor (RyR2), which is responsible for calcium release from the sarcoplasmic reticulum, and the transforming growth factor-β3 gene (TGFβ3), which regulates the production of extracellular matrix components and modulates expression of genes encoding desmosomal proteins.How the mutations of PKP2 gene and more broadly of desmosomal protein genes cause disease remains to be elucidated. It has been hypothesized that the lack of normal protein or the incorporation of mutant protein into cardiac desmosomes may provoke detachment of myocytes at the intercalated discs, particularly under condition of mechanical stress (like that occurring during competitive sports activity).4–6 As a consequence, there is a progressive myocyte death with subsequent repair by fibrofatty replacement. Life-threatening ventricular arrhythmias may occur either during the "hot phase" of myocyte death as abrupt ventricular fibrillation or later in the form of scar-related macro-reentrant ventricular tachycardia.Clinical DiagnosisThe discovery of gene mutations involved in the pathogenesis of ARVC/D has raised the possibility of molecular genetic diagnosis of ARVC/D in clinical care. PKP2 mutations have been associated with the disease frequently. Gerull et al5 first reported a 27% prevalence of PKP2 mutations among unrelated probands with ARVC/D. The 2 new reports by Dalal et al8 and Van Tintelen et al9 confirm and extend these previous observations by showing that PKP2 gene mutations are commonly found in ARVC/D patients, accounting for >40% of the cases. Furthermore, the Dutch study indicates that in familial ARVC/D even the large majority (70%) is caused by PKP2 mutations. A lower prevalence of mutant PKP2 gene has been reported by the studies of Syrris et al13 and Pilichou et al7 (11% and 16%, respectively). This discrepancy may be explained by geographic factors, small sample size, and patient selection bias. A potential limitation of both new reports8,9 is that patients not carrying PKP2 mutation might have mutations in other ARVC/D-related genes that have not been screened. In a very recent Italian series of 80 unrelated ARVC/D probands undergoing genetic screening of all known ARVC/D genes,7 13 (16%) carried a DSP mutation, 11 (14%) a PKP2 mutation, 8 (10%) a DSG2 mutation, and 2 (2.5%) a TGFβ3 mutation. According to previous and new results, molecular genetic diagnosis of ARVC/D appears to be feasible in a significant proportion of patients by screening for mutations in the PKP2 gene and more broadly in desmosomal protein genes.Task Force Diagnostic CriteriaAccording to standardized diagnostic criteria proposed by an international task force (Table),10 the diagnosis of ARVC/D is currently based on the presence of major and minor criteria encompassing ECG, arrhythmic, RV morphofunctional, histopathological, and clinical genetic factors. The diagnosis of ARVC/D is achieved in the presence of 2 major criteria or 1 major plus 2 minor or 4 minor criteria from different groups. Although task force guidelines during the last decade have represented a useful clinical approach to ARVC/D diagnosis, revisions have been proposed to increase sensitivity, particularly in the context of family screening because of incomplete disease expression. Genetic testing may represent the gold standard on which clinical diagnostic criteria can be compared. The findings of the 2 new studies support the diagnostic accuracy of current task force criteria, given that PKP2 mutations were identified in none of 12 (US study)8 and in only 2 of 40 (Dutch study)9 patients not fulfilling diagnostic criteria. Syrris et al13 reported that the use of modified criteria expanded the diagnostic yield, but it also led to false-positives, ie, family members assumed to be clinically affected but subsequently found to be gene negative. The results of previous and new studies highlight the advantages of a molecular diagnosis of ARVC/D and support the need for a revision of task force guidelines to include molecular genetic information in the family history criteria. Criteria for Clinical Diagnosis of ARVC/DMajorMinor'on'LV indicates left ventricular. Modified from Corrado et al,10 with permission.Family historyFamilial disease confirmed at necropsy or surgeryFamily history of premature sudden death (age <35 y) due to suspected ARVD/C; family history (clinical diagnosis based on present criteria)ECG depolarization/conduction abnormalitiesEpsilon waves or localized prolongation (>110 ms) of QRS complex in right precordial leads (V1 to V3)Late potentials on signal-averaged ECGECG repolarization abnormalitiesInverted T waves in right precordial leads (V2 and V3) in people aged >12 y and in absence of right bundle branch blockArrhythmiasSustained or nonsustained left bundle branch block–type ventricular tachycardia documented on ECG or Holter monitoring or during exercise testing; frequent ventricular extrasystoles (>1000/24 h on Holter monitoring)Global or regional dysfunction and structural alterationsSevere dilatation and reduction of RV ejection fraction with no or mild LV involvement; localized RV aneurysms (akinetic or dyskinetic areas with diastolic bulging); severe segmental dilatation of RVMild global RV dilatation or ejection fraction reduction with normal LV; mild segmental dilatation of RV; regional RV hypokinesiaTissue characteristics of wallsFibrofatty replacement of myocardium on endomyocardial biopsyThe major task of molecular genetic screening is to achieve a preclinical diagnosis of ARVC/D, which would be particularly useful in family members with incomplete disease expression or in patients with early/minor clinical phenotype. It is important to remember that molecular genetic testing may only support a clinical overt or suspicious diagnosis but cannot make a clinical diagnosis of ARVC/D itself. In fact, mutation carriers may either have no disease phenotype (incomplete penetrance) or present with various degree of clinical manifestations, ranging from asymptomatic family members with concealed RV structural abnormalities and no arrhythmias to patients experiencing cardiac arrest or undergoing cardiac transplantation because of right or biventricular heart failure (variable clinical expression). Inheriting a mutation does not mean that the individual will present clinical manifestation of disease: healthy mutation carriers have only inherited the risk for developing the clinical phenotype. The results of both the US8 and European9 studies are in agreement with those of previous investigations of genotype-phenotype correlation that documented a large heterogeneity in clinical expression, as a consequence not only of different desmosomal protein genes but also of different mutations within the same gene. Moreover, Syrris et al13 recently reported that strikingly different phenotypes can be observed among individuals sharing the same PKP2 gene mutation within the same family. This suggests that other genetic and environmental factors influence clinical expression.Taken together, these findings suggest that a positive genetic result can only be part of a more comprehensive clinical approach combining multiple sources of diagnostic information such as ECG, arrhythmic, morphofunctional, histopathological, and clinical/molecular genetic findings.Risk Stratification and TherapyIn both new studies,8,9 the comparison of clinical characteristics of PKP2 mutation carrier and noncarrier ARVC/D patients failed to identify a PKP2-specific clinical phenotype. No significant differences were found with regard to a series of clinical, ECG, and arrhythmic variables between the 2 groups, except for earlier clinical presentation (in the US study)8 and more prevalent right precordial repolarization abnormalities (in the Dutch study)9 among PKP2-positive individuals. In addition, in both studies the proportion of patients who received an ICD and the incidence of appropriate discharges during the follow-up did not differ between mutation-positive and mutation-negative probands, suggesting that genetic screening for PKP2 gene mutations is unlikely to contribute significantly to risk assessment. These findings are in agreement with those of genotype-phenotype correlations in other cardiomyopathies, in which genotyping has not been shown to be able to predict phenotype or prognosis on the basis of characterization of malignant versus benign mutations.The most important aim of genotyping families with ARVC/D is to identify genetically affected relatives before a malignant clinical phenotype and life-threatening ventricular arrhythmias occur. Clinical manifestations of ARVC/D usually develop during adolescence or young adulthood and are preceded by a long preclinical phase. Cardiac arrest may occur in previously asymptomatic young adults and competitive athletes as the first manifestation of disease. Young age is the most powerful independent predictor of ventricular fibrillation in patients with ARVC/D.14 All efforts should be made to genotype and manage younger family members with ARVC/D who carry the highest risk of sudden death. These efforts are justified by the recognition that timely therapy with ICD provides life-saving protection.14 Our experience during the past decade showed the favorable clinical outcome (0.08 annual mortality rate) of a large cohort of patients diagnosed with familial ARVC/D who underwent close follow-up and treatment.15 These findings underscore the importance of early diagnosis of ARVC/D by molecular genetic analysis to establish a focused prevention strategy based on lifestyle modifications (restriction from competitive sport), clinical follow-up (identification of alarming symptoms, ECG/echocardiographic abnormalities, and ventricular arrhythmias), and prophylactic therapy (β-blockers, amiodarone, and ICD) to prevent sudden death.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.DisclosuresNone.FootnotesCorrespondence to Domenico Corrado, MD, PhD, Department of Cardiac, Thoracic, and Vascular Sciences, Via Giustiniani 2, 35121 Padova, Italy. E-mail [email protected] References 1 Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988; 318: 129–133.CrossrefMedlineGoogle Scholar2 Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A, Silvestri F, Blomstrom-Lundqvist C, Wlodarska EK, Fontaine G, Camerini F. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997; 30: 1512–1520.CrossrefMedlineGoogle Scholar3 Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy or myocarditis? Circulation. 1996; 94: 983–991.CrossrefMedlineGoogle Scholar4 McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, Baboonian C, Jeffery S, McKenna WJ. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000; 355: 2119–2124.CrossrefMedlineGoogle Scholar5 Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R, Simionati B, Basso C, Thiene G, Towbin JA, Danieli GA. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002; 71: 1200–1206.CrossrefMedlineGoogle Scholar6 Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman BB, Markowitz SM, Ellinor PT, MacRae CA, Peters S, Grossmann KS, Drenckhahn J, Michely B, Sasse-Klaassen S, Birchmeier W, Dietz R, Breithardt G, Schulze-Bahr E, Thierfelder L. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004; 36: 1162–1164.CrossrefMedlineGoogle Scholar7 Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G, Vettori A, Valente M, Towbin J, Thiene G, Danieli GA, Rampazzo A. Mutations in desmoglein-2 gene are associated to arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006; 113: 1171–1179.LinkGoogle Scholar8 Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, Prakasa K, Towbin JA, Marcus FI, Spevak PJ, Bluemke DA, Abraham T, Russell SD, Calkins H, Judge DP. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006; 113: 1641–1649.LinkGoogle Scholar9 van Tintelen JP, Entius MM, Bhruiyan ZA, Jongbloed R, Wiesfeld ACP, Wilde AAM, van der Smagt J, Boven LG, Mannens MMAM, van Langen IM, Hofstra RMW, Otterspoor LC, Doevendans PAFM, Rodriguez L-M, van Gelder IC, Hauer RNW. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2006; 113: 1650–1658.LinkGoogle Scholar10 Corrado D, Fontaine G, Marcus FI, McKenna WJ, Nava A, Thiene G, Wichter T, for the Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Circulation. 2000; 101: e101–e106.LinkGoogle Scholar11 Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, Fasoli G, Scognamiglio R, Corrado D, Thiene G. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet. 1994; 3: 959–962.CrossrefMedlineGoogle Scholar12 Thiene G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification? Eur Heart J. 2004; 25: 1772–1775.CrossrefMedlineGoogle Scholar13 Syrris P, Ward D, Asimaki A, Sen-Chowdhry S, Ebrahim HY, Evans A, Hitomi N, Norman M, Pantazis A, Shaw AL, Elliott PM, McKenna WJ. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006; 113: 356–364.LinkGoogle Scholar14 Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA III, Buja G, Thiene G. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003; 108: 3084–3091.LinkGoogle Scholar15 Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, Villanova C, Daliento L, Buja G, Corrado D, Danieli GA, Thiene G. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000; 36: 2226–2233.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByHylind R, Pereira A, Quiat D, Chandler S, Roston T, Pu W, Bezzerides V, Seidman J, Seidman C and Abrams D (2022) Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis, Circulation: Genomic and Precision Medicine, 15:3, (e003507), Online publication date: 1-Jun-2022. (2022) Guidelines for Echocardiographic Diagnosis of Cardiomyopathy: Recommendations from Echocardiography Group of Ultrasound Medicine Branch in Chinese Medical Association, Echocardiography Committee of Cardiovascular Branch in Chinese Medical Association, ADVANCED ULTRASOUND IN DIAGNOSIS AND THERAPY, 10.37015/AUDT.2022.210021, 6:2, (72), . Scheel P, Giuliano K, Tichnell C, James C, Murray B, Tandri H, Carter D, Fehr T, Umapathi P, Vaishnav J, Lewsey S, Hsu S, Calkins H, Sharma K, Choi C, Gilotra N and Kilic A (2021) Heart transplantation strategies in arrhythmogenic right ventricular cardiomyopathy: a tertiary ARVC centre experience, ESC Heart Failure, 10.1002/ehf2.13757, 9:2, (1008-1017), Online publication date: 1-Apr-2022. Kohela A and van Rooij E (2022) Fibro-fatty remodelling in arrhythmogenic cardiomyopathy, Basic Research in Cardiology, 10.1007/s00395-022-00929-4, 117:1, Online publication date: 1-Dec-2022. Argirò A, Ho C, Day S, van der Velden J, Cerbai E, Saberi S, Tardiff J, Lakdawala N and Olivotto I (2022) Sex‐Related Differences in Genetic Cardiomyopathies, Journal of the American Heart Association, 11:9, Online publication date: 3-May-2022.Ezekian J, Rehder C, Kishnani P and Landstrom A (2021) Interpretation of Incidental Genetic Findings Localizing to Genes Associated With Cardiac Channelopathies and Cardiomyopathies, Circulation: Genomic and Precision Medicine, 14:4, Online publication date: 1-Aug-2021.Corrado D, Zorzi A, Cipriani A, Bauce B, Bariani R, Beffagna G, De Lazzari M, Migliore F, Pilichou K, Rampazzo A, Rigato I, Rizzo S, Thiene G, Perazzolo Marra M and Basso C (2021) Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy, Journal of the American Heart Association, 10:18, Online publication date: 21-Sep-2021. Brothers C, Etchegary H, Curtis F, Simmonds C, Houston J, Young T, Pullman D, Mariathas H, Connors S and Hodgkinson K (2021) Psychological Distress and Quality of Life in Participants Undergoing Genetic Testing for Arrhythmogenic Right Ventricular Cardiomyopathy Caused by TMEM43 p.S358L: Is It Time to Offer Population-Based Genetic Screening?, Public Health Genomics, 10.1159/000517265, 24:5-6, (253-260), . Lehman J and Williams B (2021) Syncope in a 14yo female with ventricular tachycardia; an atypical etiology, The American Journal of Emergency Medicine, 10.1016/j.ajem.2020.11.016, 45, (677.e5-677.e7), Online publication date: 1-Jul-2021. Wilhelm M (2020) Pre-participation cardiovascular evaluation of young athletes: Should they sweat or not?, European Journal of Preventive Cardiology, 10.1177/2047487319897445, 27:3, (308-310), Online publication date: 1-Feb-2020. Todica A, Siebermair J, Schiller J, Zacherl M, Fendler W, Massberg S, Bartenstein P, Cyran C, Kääb S, Hacker M, Wakili R and Lehner S (2018) Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: An 123I-metaiodobenzylguanidine SPECT/CT study, Journal of Nuclear Cardiology, 10.1007/s12350-018-01545-3, 27:6, (2402-2409), Online publication date: 1-Dec-2020. Sharma T, Habash F, Mounsey J, Baker C and Lopez Candales A Ebstein's Anomaly in Disguise: Follow the Cues and the Diagnosis Can Be Made, Cureus, 10.7759/cureus.10773 Ashraf H and Rosenthal J (2020) Right Heart Failure, Cardiology Clinics, 10.1016/j.ccl.2020.01.008, 38:2, (175-183), Online publication date: 1-May-2020. Corrado D, Zorzi A and Thiene G (2020) Specific Cardiovascular Diseases and Competitive Sports Participation: Arrhythmogenic Right Ventricular Cardiomyopathy Textbook of Sports and Exercise Cardiology, 10.1007/978-3-030-35374-2_14, (251-271), . Mattesi G, Cipriani A, Zorzi A and Corrado D (2020) Arrhythmogenic Right Ventricular Cardiomyopathy Management of Cardiac Arrhythmias, 10.1007/978-3-030-41967-7_32, (791-810), . Assis F and Tandri H (2020) Epicardial Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiac Electrophysiology Clinics, 10.1016/j.ccep.2020.05.005, 12:3, (329-343), Online publication date: 1-Sep-2020. Liang W, Gasparyan L, AlQarawi W and Davis D (2019) Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells, Expert Opinion on Biological Therapy, 10.1080/14712598.2019.1575359, 19:4, (313-333), Online publication date: 3-Apr-2019. Chen X, Peng H, Zheng C, Zhang H, Yan C, Ma H, Dai X and Li X (2019) Two pedigrees with arrhythmogenic right ventricular cardiomyopathy linked with R49H and F531C mutation in DSG2, Human Genome Variation, 10.1038/s41439-019-0069-3, 6:1, Online publication date: 1-Dec-2019. Assis F and Tandri H (2019) Mapping and Ablation in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Cardiac Mapping, 10.1002/9781119152637.ch74, (934-946) Blusztein D, Zentner D, Thompson T, Jayadeva P, Liang D, Wang R, Winship I, James P, Trainer A, Kalman J and Vohra J (2019) Arrhythmogenic Right Ventricular Cardiomyopathy: A Review of Living and Deceased Probands, Heart, Lung and Circulation, 10.1016/j.hlc.2018.07.017, 28:7, (1034-1041), Online publication date: 1-Jul-2019. Boczar K, Alqarawi W, Green M, Redpath C, Burwash I and Dwivedi G (2019) The echocardiographic assessment of the right ventricle in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia compared with athletes and matched controls, Echocardiography, 10.1111/echo.14308, 36:4, (666-670), Online publication date: 1-Apr-2019. Katarzyńska-Szymańska A, Chmielewska-Michalak L and Mitkowski P (2019) Qualification for physical activity in young adults with arrhythmias, In a good rythm, 10.5604/01.3001.0013.0500, 4:49, (12-17), Online publication date: 10-Feb-2019. Ravi S, Willis M and Schisler J (2019) Fibrotic Signaling in Cardiomyopathies Fibrosis in Disease, 10.1007/978-3-319-98143-7_10, (273-317), . Konstam M, Kiernan M, Bernstein D, Bozkurt B, Jacob M, Kapur N, Kociol R, Lewis E, Mehra M, Pagani F, Raval A and Ward C (2018) Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association, Circulation, 137:20, (e578-e622), Online publication date: 15-May-2018. Antzelevitch C (2018) OBSOLETE: Brugada Syndrome Reference Module in Biomedical Sciences, 10.1016/B978-0-12-801238-3.99794-0, . Kim J and Shah M (2018) Dysrhythmias and Ventricular Dysfunction and Heart Failure Heart Failure in the Child and Young Adult, 10.1016/B978-0-12-802393-8.00027-2, (353-368), . Etheridge S, Saarel E and Martinez M (2018) Exercise participation and shared decision-making in patients with inherited channelopathies and cardiomyopathies, Heart Rhythm, 10.1016/j.hrthm.2017.12.020, 15:6, (915-920), Online publication date: 1-Jun-2018. Antzelevitch C (2018) Brugada Syndrome Encyclopedia of Cardiovascular Research and Medicine, 10.1016/B978-0-12-809657-4.99794-1, (356-372), . Sreetharan S, MacIntyre C, Fatah M, Warren A, Wilson G and Hamilton R (2018) Clinical utility of endomyocardial biopsies in the diagnosis of arrhythmogenic right ventricular cardiomyopathy in children, Pediatric Research, 10.1038/s41390-018-0093-x, 84:4, (552-557), Online publication date: 1-Oct-2018. Mahdieh N, Najafi N, Soveizi M, Saeidi S, Noohi F, Maleki M and Rabbani B (2018) WITHDRAWN: PKP2 as a main cause of Arrhythmogenic right ventricular dysplasia in Iran: An update of the mutations around the world, Cardiovascular Pathology, 10.1016/j.carpath.2018.04.008, Online publication date: 1-May-2018. Hedley J, Al Mheid I, Alikhani Z, Pernetz M and Kim J (2017) Arrhythmogenic Right Ventricular Cardiomyopathy in an Endurance Athlete Presenting with Ventricular Tachycardia and Normal Right Ventricular Function, Texas Heart Institute Journal, 10.14503/THIJ-16-6025, 44:4, (290-293), Online publication date: 1-Aug-2017. Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Brugada Terradellas J, Carré F, Guasch E, Heidbuchel H, La Gerche A, Lampert R, Mc